Adamas Trust, Inc. will report its financial results for the third quarter and first nine months of 2026 after market close on October 28, 2026. The company will host a conference call and webcast on October 29, 2026, at 9:00 a.m. Eastern Time to discuss the results. Investors can pre-register to join the call or listen via the company's website, with a replay available for 12 months. This event provides insight into Adamas Trust's ongoing real estate investment activities and financial performance.
Adamas Trust 2026 is the subject of an upcoming financial report and conference call. For readers following the real estate sector, here is Pluang's market snapshot as of Oct 20, 2026 03:02 WIB: out of 47 priced US real estate stocks, 10 rose and 37 fell. Notable prices include EPR Properties at USD 54.30 with a -2.53% change, Alexandria Real Estate Equities Inc at USD 40.57 with a -2.52% change and 100% buy order activity, and Healthpeak Properties Inc at USD 18.41 with a -2.48% change.
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
